

Top Tier* NExT Applications

from Academia			
Applicant PI	Center	Title	Cycle
Bresnick, Anne R.	Albert Einstein College of Medicine	Development of S100A4 inhibitors	01
Deshaies, Raymond	California Institute of Technology	Small Molecule Inhibitors of ATPase P97	01
Earp, H. Shelton	University of North Carolina-Chapel Hill	Developing Small Molecule Mer Inhibitor	01
Frangioni, John V.	Beth Israel Deaconess Medical Center	NIR Fluorophore for Image-Guided Surgery	01
Grandis, Jennifer R.	University of Pittsburgh	Inhibitors of STAT3 Activation	01
Hsieh, James J.	Washington University-St. Louis/MSKCC	Optimization of Lead Small Molecule Inhibitors of Taspase 1 for Cancer Therapeutics	01
Vogelstein, Bert	Johns Hopkins University	MTAP Isogenic Drug Screen	01
Altieri, Dario C.	University of Massachusetts Medical School	Clinical Development of Mitochondrial-Targeted Hsp90 Antagonists, Gamitrinibs	02
Dang, Chi	Johns Hopkins University School of Medicine	Development of FX11, a Lactate Dehydrogenase A (LDHA) Inhibitor, as an Anti-neoplastic Agent	02
Kufe, Donald W.	Dana-Farber Cancer Institute	The Development of a Novel Anti-Cancer Agent Against the MUC1 Oncoprotein	02
Melnick, Ari	Joan & Sanford I Weill Medical College	Clinical translation of a BCL-6 inhibitor	02
Prochownik, Edward V.	Children's Hospital of Pittsburgh	Evaluation of Rationally-Designed Small Molecules Directed Against the c-Myc Oncoprotein	02
Roden, Richard B.	Johns Hopkins University	Production of an HPV16 L2E6E7 vaccine with GPI-0100 adjuvant for the treatment of HPV-associated disease	02
Frye, Stephen	University of North Carolina	Assay Development and Hit Discovery for IDH1-Based Approaches Targeting Glioblastoma	03
Alvarez, Ronald	The University of Alabama at Birmingham	A novel and high potency combination treatment using Ad5-Delta24RGD and Chemotherapy for Human Ovarian Cancer	04
Doemling, Alexander	University of Pittsburgh	p53/MDM4/MDM2 Antagonists	04
Mazar, Andrew Paul	Northwestern University	huATN-658, a humanized monoclonal antibody targeting the urokinase receptor	04
Rathmell, Wendy Kimryn	The University of North Carolina	Ror2 as a Target for Renal Carcinoma	04
Kirsch, David	Duke University Medical Center	Using Molecular Imaging to Detect Microscopic Residual Cancer During Surgery	05
Miller, Jeffrey	University of Minnesota - Twin Cities	rhIL-15 to Exploit NK cells in cancer therapy	05
Liu, Yang	University of Michigan	Development of Clinical Grade Echinomycin for Post-remission Therapy of AML	08
Rosenthal, Eben	The University of Alabama at Birmingham	Intraoperative Optical Imaging to Guide Surgical Resection of Cancer	08
Lieber, Michael	University of Southern California	Inhibitors of the Artemis Endonuclease for Cancer Chemotherapy	09
Heyer, Wolf-Dietrich	University of California Davis	Inhibitors of recombinational DNA repair	10
Fesik, Stephen	Vanderbilt University Medical Center	Discovery of subnanomolar inhibitors of Mcl-1	11

Fu, Haiyan	Emory University	Targeting oncogenic protein-protein interactions for therapeutic discovery	11
Fenical, William	Scripps Institution of Oceanography	Preclinical Development of the Seriniquinone Class of Melanoma-Selective Ag	12
Fenical, William	Scripps Institution of Oceanography	Discovery of Agents that Induce Autophagy	12
Yan, Qin	Yale University	Identifying Small Molecule Inhibitors of Histone Demethylases RBP2 and PLU1	12
Gromeier, Matthias	Duke University Medical Center	Acquisition of bulk substance (cGMP) PVS-RIPO for extended clinical studies	13
Ravetch, Jeffrey	The Rockefeller University	Agonistic anti-CD40 therapy enhanced by FcγRIIB-targeted Fc-engineering	14
Parsons, Ramon	Icahn School of Medicine at Mount Sinai	Development of PTEN-Long for Cancer Therapy	15
Salvino, Joseph	Drexel University	Lead Optimization of a Potent CX3CR1 Antagonist	15
Zhang, Shuxing	University of Texas M.D. Anderson Cancer Center	Targeting Skp2 Ubiquitination for Advanced Prostate Cancer Therapy	17
Fesik, Stephen	Vanderbilt University Medical Center	Discovery of Small Molecule Inhibitors of the WDR5-MLL1 Interaction	18
Gray, Nathanael	Dana-Farber Cancer Institute	Development of PIP4K2 Inhibitors for the Treatment of p53 Deficient Cancers	18
Markowitz, Sanford	Case Western Reserve University	SW033291 Markedly Accelerates Tri-Lineage Recovery After Marrow Transplant	19
Gillanders, William	Washington University in St Louis	Neoantigen vaccine + anti-PDL1 phase 1 clinical trial	21

from Private Sector - Biotechnology Companies

Applicant PI	Center	Title	Cycle
Leopold, Lance	Ascenta Therapeutics, Inc.	AT-406, a Pan, Oral IAP Inhibitor	01
Kovach, John S.	Lixte Biotechnology Holdings, Inc.	Novel Inhibitor of PP2A Potentiates Chemotherapy	02
Leigh, Bryan	Tracon Pharmaceuticals	Development of TRC105 as a Novel Antiangiogenic Monoclonal Antibody	02
Davis, Thomas	Celldex Therapeutics, Inc.	Clinical Development of CDX-1308 Vaccine Regimen	03
Graham, Martin	Tetralogic Pharmaceuticals	Predictive Biomarkers of SMAC-Mimetic (TL32711) Efficacy in Ovarian Cancer	04
Paradiso, Linda J.	America Stem Cell, Inc.	Accelerated Hematopoietic Recovery with ASC101	04
Roninson Porter, Igor	Senex Biotechnology, Inc.	Optimization and testing of CDK3 inhibitors	04
Frankel, Stanley	Micromet	Blinatumomab Clinical Development for B-lineage Malignancies	05
Hamdy, Ahmed	Pharmacyclics, Inc.	PCI-32765, Btk inhibitor for B-cell malignancies	05
Klein, Pamela	Intellikine, Inc.	INK128 a TORC1/2 inhibitor in solid tumors and hematologic malignancies	06
Frye, John	Exelixis, Inc.	XL184 (Cabozantinib)	07
Miller, Langdon	Gilead (formerly Calistoga)	CAL-101 for Patients with Neoplastic Diseases	07
Hussein, Mohamad	Celgene Corporation	Pomalidomide in Rare Diseases with Unmet Medical Needs	08
Leigh, Bryan	Tracon Pharmaceuticals	Development of TRC102 as a Novel Inhibitor of Base Excision Repair	08
Wagner, Anthony	Amgen Incorporated	Ganitumab (AMG 479) CRADA	08

Leopold, Lance	Incyte Corporation	INCB024360, ANovel Orally-Administered IDO 1 Inhibitor for Cancer Treatment	09
Orton, Darren	StemSynergy Therapeutics, Inc.	Development of a Wnt Inhibitor	09
Wolchok, Jedd	Memorial Sloan-Kettering Cancer Center	Manufacturing of a VRP-TRP2 Vaccine for a Phase I Clinical Trial	10
Tabakoff, Boris	Lohocla Research Corporation	Cancer and Cancer Therapy Induced Neuropathic Pain: Treatment Prevention	11
Dorr, Andrew	BioMarin Parmaceutical Inc.	Patient Selection Assay Strategies to Predict Patients That Respond to PARP	12
Hergenrother, Paul	Vanquish Oncology, Inc.	Toward an IND Filing for Procaspace-3 Activating Compounds	13
Fields, Scott	Vertex Pharmaceuticals Inc	VX-970 a novel ATR inhibitor for clinical development in cancer patients	15
Fields, Scott	Vertex Pharmaceuticals Inc	VXc-984 a novel DNA-PK inhibitor for development in cancer patients	15
Isaacman, Steven	Nanometics LLC	An orally available therapeutic for triple negative breast cancer	15
Quackenbush, Elizabeth	Celldex Therapeutics, Inc.	Continued Development of the Antibody-drug Conjugate CDX-011	15
Tweardy, David	StemMed, Ltd.	Oral Stat3 Inhibitor	16
Allen, Andrew	Clovis Oncology, Inc.	Combination therapies to overcome CO-1686 resistance in mutant EGFR NSCLC	17
Brown, Bob	Dicerna Pharmaceuticals, Inc.	Efficacy of DCR-MYC in Patient-Derived Xenograft Models	17
Brown, Bob	Dicerna Pharmaceuticals, Inc.	β -catenin/CTNNB1 DsiRNA LNP therapeutic for HCC and CRC	17
Carpi, David	Targeted Therapy Technologies, LLC	Episcleral Antineoplastic Interventions for Pediatric Retinoblastoma	17
Davis, Thomas	Celldex Therapeutics, Inc.	Continued Development of the Varlilumab (CDX-1127)	17
Matthews, Bill	Leuchemix, Inc.	Clinical and Manufacturing Support for LC-1	18
Holsapple, Earle	SciTech Development, LLC	nanoFenretinide Drug Products for Treating Mycosis Fungoides and its Leukemia	19
Keilhack, Heike	Epizyme, Inc.	EZH2 Inhibitor Tazemetostat as Novel Cancer Therapy	20
Cox, Michael	Loxo Oncology, Inc	Development of LOXO-101, a pan TRK-inhibitor, in hematologic malignancies	21
Blakemore, Stephen	Epizyme, Inc.	Pinometostat (EPZ-5676) NCI-CTEP Collaboration Proposal	21

from Private Sector – Pharmaceutical Companies

Applicant PI	Center	Title	Cycle
Marapaka, Praveen	MedImmune	HA 22 Randomized PIII-HCL	03
Huszar, Dennis	AstraZeneca	AZD1480 JAK1/2 Inhibitor	04
Fleming, Ronald	GlaxoSmithKline	GSK2118436 BRAF Inhibitor	05
Levin, Jeremy	GlaxoSmithKline	Oral MEK inhibitor GSK1120212	06
Johnson, Lisa	Bristol-Myers Squibb	BMS-936558 Anti-PD-1 Antibody Treatment of Cancer	11
Pluda, James	Merck	Merck agent MK-3475, an Anti-PD1 Monoclonal Antibody (mAb)	11
Watson, Patricia	Merck	HDM2; MK-8242 NExT Application	11
Yao, Siu-Long	Merck	Vintafolide: MK-8109	12
Wadsworth, Catherine	AstraZeneca	AZD9291 3rd Generation EGFR TKI Next Partnership With NCI	15

		Application.	
Wagner, Anthony	Amgen Incorporated	AMG 337 NExT Application	15
Healy, Denis	Kyowa Hakko Kirin Pharma, Inc.	Mogamulizumab (a Recombinant, Humanized Monoclonal Antibody)	16
Wadsworth, Catherine	Medimmune	AstraZeneca/MedImmune Cancer Immunotherapy Portfolio NExT Application	16
Woodard, J. Paul	Genentech, Inc.	Genentech MPDL3280A NCI NExT Application 2/15/2014	16
Wagner, Anthony	Amgen Incorporated	Talimogene Laherparepvec NExT Application	18
Barry, Simon	AstraZeneca AB	AZD8186 Targeting PI3Kbeta and delta for Solid and Hematological Tumors	18
Wagner, Anthony	Amgen Incorporated	AMG 232 NExT Application	19
Amakye, Dereck	Bayer HealthCare Pharmaceuticals	Copanlisib, a pan-Class I PI3K inhibitor for Combination Studies	21
Amakye, Dereck	Bayer HealthCare Pharmaceuticals	Anetumab Ravansine, Novel Mesothelin Directed Drug Conjugate Combo Studies	21
D'Cruz, Celina	AstraZeneca	Savolitinib (AZD6094) is a highly potent and selective MET inhibitor with demonstrated clinical activity in solid tumors	21

from Non-Profit Organizations

Applicant PI	Center	Title	Cycle
Reed, John C.	Sanford-Burnham Medical Research Institute	Chemical Activators of the PML Tumor Suppressor Pathway	01
Reed, John C.	Sanford-Burnham Medical Research Institute	Chemical Modulators of Autophagy	01
Sadar, Marianne	British Columbia Cancer Agency	IND-Directed Preclinical Studies of EPI-001 for Prostate Cancer Treatment	03
Cravatt, Benjamin	The Scripps Research Institute	Development of Monoacylglycerol-Lipase Inhibitors for Cancer Therapy	06
Thottassery, Jaideep	Southern Research Institute	Preclinical Development of T-dCyd: A New Epigenetic Agent	07
Ronai, Ze'ev	Sanford-Burnham Medical Research Institute	Chemical Inducers of ATF2-mediated Apoptotic Activity in Melanoma	09
Hazlehurst, Lori	H. Lee Moffitt Cancer Center & Research Institute	Development Of MTI-101 for the Treatment Of Relapsed Multiple Myeloma	12
Laderoute, Keith	SRI International	5'-AMP-Activated Protein Kinase Inhibitors as Novel Cancer Therapeutics	13
Hazlehurst, Lori	H. Lee Moffitt Cancer Center & Research Institute	Development Of MTI-101 for the Treatment Of Relapsed Multiple Myeloma	16
Federspiel, Mark	Mayo Clinic	Phase 2 Clinical Trial Treating Patients with Refractory Multiple Myeloma	17
Schwab, Matthias	Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology	Supplementation of TAMoxifen standard therapy with ENDOxifen in breast cancer patients	21

from Government

Applicant PI	Center	Title	Cycle
Waldmann, Thomas	Center for Cancer Research, NIH	Anti-IL-15 Receptor Antibody Therapy of Celiac Disease Associated Lymphoma	03

Choyke, Peter	Center for Cancer Research, NIH	A Phase II Study of F-18 DCFBC, A Prostate Specific Membrane Antigen-Target	11
Griffiths, Gary	Center for Cancer Research, NIH	Large Scale Preparation of IR700-Panitumumab for Clinical Use	14
Marugan, Juan	National Center for Advancing Translational Sciences, NIH	Metarrestin, A New Approach Towards Metastasis	16
Harris, Curtis	Center for Cancer Research, NIH	Anti-miR-21 Therapeutics to Treat and Prevent Metastatic Colon Cancer	18
Leppla, Stephen	National Institute of Allergy and Infectious Diseases, NIH	Protease-activated Anthrax toxin for the treatment of human solid tumors	21

*Top Tier applications are not guaranteed to be accepted into the NExT Program